Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

No longer recruiting (closed or complete)Last updated: 7 February 2024

This Phase I trial is evaluating the effectiveness of a new cancer treatment (PTM-101) in people with boderline resectable or locally advanced pancreatic cancerA Phase I Study of PTM-101 as Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Trial purpose

Medical clipboardCancer treatment

Tumor type

Upper gastrointestinal tract Cancers Upper gastrointestinal tract

Age

People18+

Clinical summary

Summary

PTM-101 is a biodegradable device containing 100mg of paclitaxel. PTM-101 will be placed onto the pancreatic surface overlying the tumour via a laparoscopy. PTM-101 will degrade over approximately 10 weeks.

Conditions

This trial is treating people with pancreatic ductal adenocarcinoma

Eligibility

Inclusion

1. EUS accessible, biopsy proven PDAC with borderline resectable or locally advanced disease by imaging criteria in accordance with International Consensus Guidelines (S Isaji, 2018)
2. No radiographic evidence of metastatic disease
3. No prior therapy for PDAC
4. ECOG 0 or 1
5. Clinically determined to be able to tolerate neoadjuvant therapy

Exclusion

 

1. Any other active malignancy
2. Known HIV or active viral hepatitis
3. Active ongoing infection or autoimmune disease which would preclude administration of chemotherapy or surgical intervention
4. Inability to comply with activities and therapeutic interventions as outlined
5. Currently enrolled in another investigational drug or device trial
6. Women who are pregnant or breastfeeding

Inclusion

  • Your cancer has not spread to other parts of the body (localised).

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

No longer recruiting (closed or complete) hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:

Trial sponsor

PanTher Therapeutics and Avania Clinical

Scientific Title

A Phase I Study of PTM-101 as Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information